Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
INCY
$106.87
$0.95
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Next Earnings
2026-01-11
Beta
0.82
Average Volume
2348040
Market Cap
20981007270
Last Dividend
0
CIK
0000879169
ISIN
US45337C1027
CUSIP
45337C102
CEO
William Meury
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
2617
IPO Date
1993-11-04
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Mohamed Khairie Issa Sells 10,856 Shares of Incyte (NASDAQ:INCY) Stock | Incyte Corporation (NASDAQ: INCY - Get Free Report) EVP Mohamed Khairie Issa sold 10,856 shares of the company's stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $109.07, for a total transaction of $1,184,063.92. Following the completion of the sale, the executive vice president directly owned 66,132 shares | Defense World | 2026-01-10 05:04:57 |
| Why Investors Need to Take Advantage of These 2 Medical Stocks Now | Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP. | Zacks Investment Research | 2026-01-07 09:55:20 |
| Incyte: Maintaining Buy Rating As Hem/Oncology Portfolio Adds 2 Recent Wins | Incyte Corporation remains a Buy, driven by robust Hem/Oncology portfolio growth and key Monjuvi/Minjuvi expansion catalysts. INCY's Hem/Onc portfolio revenues surged 107% YoY in Q3 2025, fueled by Monjuvi/Minjuvi and Niktimvo performance. Positive phase 3 frontMIND data for Monjuvi enables a 1st-line DLBCL sBLA filing in H1 2026, expanding addressable market. | Seeking Alpha | 2026-01-06 14:18:57 |
| INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma | Incyte's phase III study of Monjuvi combo for first-line DLBCL treatment met primary and key secondary goals, paving the way for a 2026 FDA filing. | Zacks Investment Research | 2026-01-06 11:20:47 |
| Incyte Study Shows Lymphoma Drug Combo Slows Aggressive Blood Cancer | Incyte Corporation (NASDAQ: INCY) on Monday shared topline results from the pivotal Phase 3 frontMIND trial of tafasitamab (Monjuvi/Minjuvi) combo as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL). | Benzinga | 2026-01-05 11:59:47 |
| Incyte's blood cancer therapy meets main goal in late-stage trial | Incyte said on Monday its experimental combo therapy met the main goal in a late-stage trial testing patients with a type of blood cancer. | Reuters | 2026-01-05 07:40:04 |
| Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma | WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for DLBCL. | Business Wire | 2026-01-05 07:30:00 |
| CWA Asset Management Group LLC Acquires New Holdings in Incyte Corporation $INCY | CWA Asset Management Group LLC bought a new position in Incyte Corporation (NASDAQ: INCY) during the undefined quarter, according to its most recent filing with the SEC. The institutional investor bought 70,204 shares of the biopharmaceutical company's stock, valued at approximately $5,954,000. A number of other hedge funds have also recently made changes | Defense World | 2026-01-05 04:26:42 |
| Generali Asset Management SPA SGR Reduces Holdings in Incyte Corporation $INCY | Generali Asset Management SPA SGR reduced its stake in Incyte Corporation (NASDAQ: INCY) by 20.3% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 24,654 shares of the biopharmaceutical company's stock after selling 6,280 shares during the quarter. Generali Asset Management SPA SGR's | Defense World | 2026-01-04 05:36:52 |
| Perigon Wealth Management LLC Purchases Shares of 5,365 Incyte Corporation $INCY | Perigon Wealth Management LLC purchased a new stake in shares of Incyte Corporation (NASDAQ: INCY) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 5,365 shares of the biopharmaceutical company's stock, valued at approximately $455,000. Several other institutional investors have also modified their | Defense World | 2026-01-03 05:18:55 |
| Continuum Advisory LLC Buys 5,185 Shares of Incyte Corporation $INCY | Continuum Advisory LLC increased its stake in Incyte Corporation (NASDAQ: INCY) by 7.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 73,825 shares of the biopharmaceutical company's stock after acquiring an additional 5,185 shares during the period. Continuum | Defense World | 2025-12-30 05:01:08 |
| 22,200 Shares in Incyte Corporation $INCY Purchased by Burney Co. | Burney Co. bought a new stake in Incyte Corporation (NASDAQ: INCY) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 22,200 shares of the biopharmaceutical company's stock, valued at approximately $1,883,000. Other institutional investors also recently made changes to | Defense World | 2025-12-28 04:50:47 |
| Incyte (NASDAQ:INCY) Insider Thomas Tray Sells 600 Shares of Stock | Incyte Corporation (NASDAQ: INCY - Get Free Report) insider Thomas Tray sold 600 shares of Incyte stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $98.25, for a total value of $58,950.00. Following the completion of the transaction, the insider directly owned 22,973 shares in the | Defense World | 2025-12-23 06:05:08 |
| Incyte (INCY) Soars 5.5%: Is Further Upside Left in the Stock? | Incyte (INCY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. | Zacks Investment Research | 2025-12-22 10:06:06 |
| Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma | TOKYO--(BUSINESS WIRE)---- $INCY--Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for Relapsed/Refractory Follicular Lymphoma. | Business Wire | 2025-12-22 02:44:00 |
| Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer | TOKYO--(BUSINESS WIRE)---- $INCY--Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer. | Business Wire | 2025-12-22 02:42:00 |
| EC Approves Label Expansion of INCY's Lymphoma Drug Minjuvi | INCY wins EC approval expanding Minjuvi's label, adding a new indication for relapsed or refractory follicular lymphoma after prior therapy. | Zacks Investment Research | 2025-12-18 10:31:25 |
| Best Defensive Stocks To Balance Tech Sector Volatility | December's mixed performance for tech may be an early signal that leadership is narrowing, especially among the value-stretched stocks. Investors looking forward to 2026 may find better risk-adjusted opportunities in defensive sectors with select growth drivers. Rather than relying solely on traditional names, this article digs deeper into Quant Strong Buys that combine durable cash flows, essential services, and key growth metrics. | Seeking Alpha | 2025-12-18 08:30:00 |
| Incyte to Present at Upcoming Investor Conference | WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the 44th Annual J. P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 am (PST). The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discover. | Business Wire | 2025-12-18 08:00:00 |
| Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma | WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma. | Business Wire | 2025-12-17 11:20:00 |
| Incyte Announces Change to its Board of Directors | WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Change to its Board of Directors. | Business Wire | 2025-12-12 08:30:00 |
| Here's Why Incyte (INCY) is a Strong Value Stock | Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. | Zacks Investment Research | 2025-12-11 10:40:21 |
| Calls of the Day: Netflix, Thermo Fisher, Incyte and Shake Shack | The Investment Committee debate the latest Calls of the Day. | CNBC Television | 2025-12-09 12:59:53 |
| Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia | WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH2025--Updated Positive Data at ASH 2025 Reinforce the Potential of Incyte's INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in ET. | Business Wire | 2025-12-08 16:30:00 |
| Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status | INCY secures FDA Breakthrough Therapy status for INCA033989 after early data show rapid and sustained platelet normalization in essential thrombocythemia patients. | Zacks Investment Research | 2025-12-08 11:31:07 |
| Incyte's New Therapy Shows Signs Of 'Disease-Modifying' Potential In Rare Blood Cancer | Early ASH 2025 data shows Incyte's INCA033989 delivers spleen, anemia and symptom improvements in mutCALR myelofibrosis. | Benzinga | 2025-12-08 09:27:13 |
| First Trust Advisors LP Sells 12,101 Shares of Incyte Corporation $INCY | First Trust Advisors LP reduced its position in shares of Incyte Corporation (NASDAQ: INCY) by 1.6% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 761,227 shares of the biopharmaceutical company's stock after selling 12,101 shares during the quarter. First Trust Advisors LP | Defense World | 2025-12-08 04:50:43 |
| Incyte Corporation (INCY) Discusses mutCALR Data and Therapeutic Advances in Myeloproliferative Neoplasms at ASH Transcript | Incyte Corporation (INCY) Discusses mutCALR Data and Therapeutic Advances in Myeloproliferative Neoplasms at ASH Transcript | Seeking Alpha | 2025-12-07 18:23:12 |
| Incyte Gets FDA Breakthrough Therapy Fast Track For Rare Blood Cancer Drug | The FDA granted Breakthrough Therapy status to Incyte's experimental treatment for a rare blood cancer. Incyte stock is basing near five-year highs. | Investors Business Daily | 2025-12-07 12:58:58 |
| Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025 | WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH2025--Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with MF Presented at ASH 2025. | Business Wire | 2025-12-07 09:30:00 |
| Incyte's First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA | WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH2025--Incyte's First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA. | Business Wire | 2025-12-07 09:30:00 |
| Incyte: Buy At This Inflection Point | Incyte Corporation's rapid non-Jakafi portfolio growth and strong operating leverage look decent amid still-cheap valuation, supporting attractive risk-reward over the coming quarters ahead. Q3 revenue beat consensus by 9%, with Jakafi still 58% of sales as rapidly expanding Opzelura, Niktimvo, Monjuvi, and Zynyz materially de-risking concentration on Jakafi. Management guides for flat OpEx and rising revenues into FY2025, supporting sustained margin expansion and robust EPS growth potential post-2029. | Seeking Alpha | 2025-12-06 09:00:00 |
| Incyte Corporation $INCY Shares Bought by Fisher Asset Management LLC | Fisher Asset Management LLC boosted its stake in shares of Incyte Corporation (NASDAQ: INCY) by 74.6% during the undefined quarter, according to its most recent filing with the SEC. The firm owned 29,922 shares of the biopharmaceutical company's stock after purchasing an additional 12,785 shares during the period. Fisher Asset Management LLC's holdings | Defense World | 2025-12-06 04:08:49 |
| Incyte Corporation (NASDAQ:INCY) Receives Consensus Recommendation of “Hold” from Brokerages | Shares of Incyte Corporation (NASDAQ: INCY - Get Free Report) have received an average rating of "Hold" from the nineteen brokerages that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, eleven have assigned a hold recommendation and seven have given a buy recommendation to the company. The | Defense World | 2025-12-04 01:57:02 |
| Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4). | Business Wire | 2025-12-03 16:30:00 |
| Incyte Corporation (INCY) Presents at Evercore 8th Annual Healthcare Conference Transcript | Incyte Corporation (INCY) Presents at Evercore 8th Annual Healthcare Conference Transcript | Seeking Alpha | 2025-12-03 15:13:37 |
| Global Vitiligo Foundation Applauds Partnership Between Incyte and Winnie Harlow to Elevate Awareness and Understanding of Vitiligo | MECHANICSBURG, Pa.--(BUSINESS WIRE)--The Global Vitiligo Foundation (GVF) commends the newly announced partnership between Incyte and supermodel and beauty entrepreneur Winnie Harlow, who together are bringing national attention to vitiligo through The Power of Choice campaign. Vitiligo affects an estimated 1.9 to 2.8 million people in the United States, yet awareness and understanding of the condition remain limited. Through personal storytelling and education, this campaign seeks to foster em. | Business Wire | 2025-12-03 08:00:00 |
| Arrowstreet Capital Limited Partnership Boosts Stock Position in Incyte Corporation $INCY | Arrowstreet Capital Limited Partnership lifted its position in shares of Incyte Corporation (NASDAQ: INCY) by 701.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,730,648 shares of the biopharmaceutical company's stock after acquiring an additional 2,390,084 shares | Defense World | 2025-12-03 03:21:00 |
| Incyte Corporation (INCY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript | Incyte Corporation (INCY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript | Seeking Alpha | 2025-12-02 14:03:24 |
| Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding | WILMINGTON, Del.--(BUSINESS WIRE)--Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding. | Business Wire | 2025-12-02 09:15:00 |
| Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel | WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel. | Business Wire | 2025-12-01 08:00:00 |
| Incyte (INCY) Up 17.2% Since Last Earnings Report: Can It Continue? | Incyte (INCY) reported earnings 30 days ago. What's next for the stock? | Zacks Investment Research | 2025-11-27 12:31:13 |
| Incyte: This Profitable Biotech Trades Like A Melting Iceberg | Incyte's Jakafi LOE overhang masked a quietly transforming, profitable biotech whose non‑Jakafi portfolio is now compounding fast enough to support a structural rerating, despite 2028 risks. Q3 2025 showcased 20% sales growth, 200%+ EBIT expansion, and EPS up 111%, proving operating leverage and validating management's shift of capital into higher‑return franchises. I view CALR antibody 989, povorcitinib in HS, and two de‑risking solid‑tumor agents as multiple, independent shots at post‑Jakafi multi‑billion‑dollar revenue pillars. | Seeking Alpha | 2025-11-27 04:09:59 |
| Incyte: Riding Jakafi, Bracing For Generic Headwinds | Incyte Corporation is undervalued, with high revenue growth, strong margins, and a 12.7% upside to a $115 target price; rated Buy. INCY's Q3 results beat expectations, driven by Jakafi and Opzelura sales, improved profitability, and disciplined R&D spending. Key risks include heavy reliance on Jakafi, with generics expected in 2028, and the pipeline's limited ability to fully offset lost revenue. | Seeking Alpha | 2025-11-27 01:11:26 |
| Why Incyte (INCY) is a Top Momentum Stock for the Long-Term | Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. | Zacks Investment Research | 2025-11-20 10:51:08 |
| Why Incyte (INCY) is a Top Value Stock for the Long-Term | The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. | Zacks Investment Research | 2025-11-19 10:46:07 |
| Incyte to Present at Upcoming Investor Conferences | WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of December: Citi's 2025 Global Healthcare Conference on Tuesday, December 2, 2025 at 11:15 am (EST) 8th Annual Evercore Healthcare Conference on Wednesday, December 3, 2025 at 1:20 pm (EST) The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmac. | Business Wire | 2025-11-19 08:00:00 |
| Incyte Corporation (INCY) Presents at Jefferies London Healthcare Conference 2025 Transcript | Incyte Corporation ( INCY ) Jefferies London Healthcare Conference 2025 November 18, 2025 6:00 AM EST Company Participants William Meury - CEO, President & Director Pablo Cagnoni - President and Head of Research & Development Conference Call Participants Yuxi Dong - Jefferies LLC, Research Division Presentation Yuxi Dong Jefferies LLC, Research Division All right. Good morning. | Seeking Alpha | 2025-11-18 13:48:53 |
| 3 Best Healthcare Stocks: Quant Strong Buys From Goldman's 'Alpha' List | The healthcare sector's renewed momentum offers fertile ground for investors wanting to outperform by picking the best stocks from the broader indexes. Goldman Sachs identified 29 healthcare stocks in the Russell 1000 universe with positive recent consensus revisions to 2026 EPS estimates and that trade at attractive valuations. Goldman sees "more opportunity for alpha than beta" as wide return dispersion and increasing M&A activity in healthcare may favor selected winners. | Seeking Alpha | 2025-11-17 16:05:39 |
| Incyte Announces Positive CHMP Opinion for Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL) | MORGES, Switzerland--(BUSINESS WIRE)---- $INCY--Incyte Announces Positive CHMP Opinion for Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL). | Business Wire | 2025-11-17 01:00:00 |
| Incyte Corporation (INCY) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript | Incyte Corporation ( INCY ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 10, 2025 10:00 AM EST Company Participants William Meury - CEO, President & Director Pablo Cagnoni - President and Head of Research & Development Conference Call Participants Michael Schmidt - Guggenheim Securities, LLC, Research Division Presentation Michael Schmidt Guggenheim Securities, LLC, Research Division All right. So welcome to this fireside chat with Incyte. | Seeking Alpha | 2025-11-10 13:51:31 |
| Incyte's Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema | WILMINGTON, Del.--(BUSINESS WIRE)--Incyte's Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema. | Business Wire | 2025-11-06 09:15:00 |
| Top Biotech Stocks Riding The Rally | Biotech stocks have rebounded after years of underperformance but remain well below their 2021 highs. Successful drug launches, strong trial results, and falling interest rates have boosted stock prices, while M&A activity pushes valuations higher. The biotech rally could be sustainable, analysts say, with biotech firms more disciplined and increasingly profitable, while startups avoid launching premature IPOs. | Seeking Alpha | 2025-11-04 15:15:35 |
| Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors | Incyte secures an exclusive option to acquire Prelude's mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with myeloproliferative neoplasms (MPNs) Prelude to receive a $35 million upfront payment and $25 million strategic equity investment, $100 million if Incyte were to exercise the option to acquire the program, and up to $775 million in additional potential milestones plus royalties on net sales Prelude will continue to develop all JAK2V617F program assets during the option period; if optioned, Incyte would lead development and commercialization globally WILMINGTON, Del., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq:PRLD), a clinical-stage precision oncology company, today announced an exclusive option agreement with Incyte (Nasdaq:INCY) focused on Prelude's previously undisclosed mutant selective JAK2V617F JH2 inhibitor program in development for patients with myeloproliferative neoplasms (MPNs). | GlobeNewsWire | 2025-11-04 07:01:00 |
| Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting | WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH2025--Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting. | Business Wire | 2025-11-03 09:31:00 |
| Bessemer Group Inc. Reduces Stock Holdings in Incyte Corporation $INCY | Bessemer Group Inc. reduced its stake in Incyte Corporation (NASDAQ: INCY) by 60.4% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,467 shares of the biopharmaceutical company's stock after selling 9,859 shares during the period. Bessemer Group Inc.'s holdings in | Defense World | 2025-11-03 03:35:39 |
| 4 Best Value And Growth Stocks (Yes, They Can Coexist) | The current market is all about momentum, but investors don't need to buy overpriced high-growth stocks to participate in gains. If you dig deep enough, you can find undervalued stocks with growth potential in both the short term and the long run. Across varied sectors like healthcare, technology, and finance, as well as non-U.S. countries with growth potential, a select group of stocks can combine those qualities. | Seeking Alpha | 2025-10-30 08:00:00 |
| Incyte to Present at Upcoming Investor Conferences | WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of November: Guggenheim Annual Healthcare Innovation Conference on Monday, November 10, 2025 at 10:00 am (EST) Jefferies Global Healthcare Conference (London) on Tuesday, November 18, 2025 at 11:00 am (GMT) The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A g. | Business Wire | 2025-10-30 08:00:00 |
| Knight Therapeutics Announces Approval and Launch of MINJUVI® (tafasitamab) in Argentina | MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM S.A. has obtained the regulatory approval and has launched MINJUVI® in Argentina. Knight obtained approval from the Argentinian health regulatory agency, ANMAT, for MINJUVI® (tafasitamab) in combination with lenalidomide, followed by MINJUVI® monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), who are not eligible for autologous stem cell transplantation (ASCT). | GlobeNewsWire | 2025-10-30 07:30:00 |
| Asset Management One Co. Ltd. Has $5.94 Million Stock Position in Incyte Corporation $INCY | Asset Management One Co. Ltd. lowered its position in shares of Incyte Corporation (NASDAQ: INCY) by 3.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 87,269 shares of the biopharmaceutical company's stock after selling 2,762 shares during the | Defense World | 2025-10-29 03:38:57 |
| Incyte: Maintaining Buy As 2 Untapped Opportunities Emerge In Oncology Portfolio | Incyte Corporation remains a Buy supported by strong Q3 2025 earnings, robust revenue growth, and raised full-year 2025 guidance. INCY advances its pipeline with promising data for povorcitinib in HS, PN, vitiligo, and asthma, with regulatory filings expected by early 2026. Oncology portfolio expansion is driven by INCA33890 for MSS colorectal cancer and INCB161734 for KRASG12D-mutated PDAC, both showing encouraging response rates. | Seeking Alpha | 2025-10-28 17:51:38 |
| Incyte Delivers Robust Growth, But 2028 Patent Expiry Still Looms | Incyte Corporation's (NASDAQ:INCY) third-quarter revenue was $1.37 billion. The company beat the consensus of $1.26 billion. | Benzinga | 2025-10-28 14:44:20 |
| INCY's Q3 Earnings & Revenues Beat Estimates on Higher Product Sales | Incyte posts strong Q3 results as higher sales of Jakafi, Opzelura and new launches drive revenue and earnings beats. | Zacks Investment Research | 2025-10-28 12:11:07 |
| Incyte Corporation (INCY) Q3 2025 Earnings Call Transcript | Incyte Corporation (NASDAQ:INCY ) Q3 2025 Earnings Call October 28, 2025 8:00 AM EDT Company Participants Alexis Smith William Meury - CEO, President & Director Pablo Cagnoni - President and Head of Research & Development Thomas Tray - Principal Financial Officer, VP of Finance & Chief Accounting Officer Steven Stein - Executive VP & Chief Medical Officer Mohamed Issa - Executive Vice President & Head of U.S. Oncology Conference Call Participants Tazeen Ahmad - BofA Securities, Research Division Andrew Berens - Leerink Partners LLC, Research Division Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Jay Olson - Oppenheimer & Co. Inc., Research Division James Shin - Deutsche Bank AG, Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division Peter Lawson - Barclays Bank PLC, Research Division Evan Seigerman - BMO Capital Markets Equity Research Derek Archila - Wells Fargo Securities, LLC, Research Division Ashwani Verma - UBS Investment Bank, Research Division Reni Benjamin - Citizens JMP Securities, LLC, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Srikripa Devarakonda - Truist Securities, Inc., Research Division Presentation Operator Greetings, and welcome to the Incyte Third Quarter 2025 Earnings Conference Call webcast [Operator Instructions]. As a reminder, this conference is being recorded. | Seeking Alpha | 2025-10-28 11:41:51 |
| Incyte (INCY) Reports Q3 Earnings: What Key Metrics Have to Say | While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. | Zacks Investment Research | 2025-10-28 10:30:51 |
| Incyte (INCY) Tops Q3 Earnings and Revenue Estimates | Incyte (INCY) came out with quarterly earnings of $2.26 per share, beating the Zacks Consensus Estimate of $1.66 per share. This compares to earnings of $1.07 per share a year ago. | Zacks Investment Research | 2025-10-28 09:16:13 |
| Incyte boosts annual sales forecast of blood cancer drug after strong quarter | Drugmaker Incyte Corp on Tuesday raised its annual sales forecast for its blood cancer treatment Jakafi after robust demand for the drug helped the company surpass Wall Street estimates for third-quarter revenue and profit. | Reuters | 2025-10-28 08:02:58 |
| Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates | WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates. | Business Wire | 2025-10-28 07:00:00 |
| Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery System | WILMINGTON, Del. & CINCINNATI--(BUSINESS WIRE)---- $INCY--Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery System. | Business Wire | 2025-10-27 07:30:00 |
| Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis | WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ISAD2025--Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis. | Business Wire | 2025-10-25 19:55:00 |
| Incyte Gears Up to Report Q3 Earnings: Is a Beat in the Cards? | INCY eyes strong Q3 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues. | Zacks Investment Research | 2025-10-24 11:02:00 |
| Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial | This trial is the first and largest study specifically designed to evaluate children and adolescents with severe alopecia areata, a population often underrepresented in clinical trials New data show 71% of adolescents with severe disease treated with baricitinib 4 mg achieved successful scalp hair regrowth at one year, with continuous improvements observed throughout those 52 weeks Lilly intends to submit the BRAVE-AA-PEDS data to global regulators for a potential label update for baricitinib (commercially available as Olumiant) INDIANAPOLIS , Oct. 24, 2025 /PRNewswire/ -- New results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) showed once-daily, oral baricitinib 4 mg helped the majority of adolescent patients (ages 12 to 1 month to | PRNewsWire | 2025-10-24 06:45:00 |
| Why Investors Need to Take Advantage of These 2 Medical Stocks Now | Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates. | Zacks Investment Research | 2025-10-23 09:51:15 |
| Incyte: Strong Growth, Margin Expansion, And Low Valuation | Incyte Corporation offers strong growth potential and a low valuation, driven by expanding margins and a robust earnings outlook. INCY's revenue is anchored by Jakafi, but a diverse pipeline and potential acquisitions could offset future patent expirations. Growth is expected from products like Monjuvi, Opzelura, Niktimvo, and pipeline compounds such as 989 and povorcitinib. | Seeking Alpha | 2025-10-21 23:13:19 |
| Incyte (INCY) Earnings Expected to Grow: Should You Buy? | Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. | Zacks Investment Research | 2025-10-21 11:06:41 |
| Incyte Corporation (INCY) Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic Cancer Transcript | Incyte Corporation (NASDAQ:INCY ) Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic Cancer October 19, 2025 1:30 PM EDT Company Participants Pablo Cagnoni - President and Head of Research & Development Patrick Mayes - Vice President of Biotherapeutic Research Ekaterine Asatiani Steven Stein - Executive VP & Chief Medical Officer Conference Call Participants Evan Seigerman - BMO Capital Markets Equity Research Michael Schmidt - Guggenheim Securities, LLC, Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division Reni Benjamin - Citizens JMP Securities, LLC, Research Division Eric Schmidt - Cantor Fitzgerald & Co., Research Division Marc Frahm - TD Cowen, Research Division Presentation Pablo Cagnoni President and Head of Research & Development We're going to get started. Thank you, everyone, for joining us here in Berlin, and there are many more of you that are online. | Seeking Alpha | 2025-10-20 17:24:31 |
| Are You Looking for a Top Momentum Pick? Why Incyte (INCY) is a Great Choice | Does Incyte (INCY) have what it takes to be a top stock pick for momentum investors? Let's find out. | Zacks Investment Research | 2025-10-20 13:00:44 |
| Will Positive Regulatory Updates Further Boost INCY Stock? | Incyte's strong 2025 performance is fueled by Jakafi's sustained growth and label expansion of Opzelura. | Zacks Investment Research | 2025-10-20 10:31:29 |
| Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma | WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ESMO25--Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced CRC and KRAS G12D Inhibitor in Advanced PDAC. | Business Wire | 2025-10-19 13:30:00 |
| INCY or ARGX: Which Is the Better Value Stock Right Now? | Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks? | Zacks Investment Research | 2025-10-16 12:41:10 |
| 3 Biotech Stocks I Am Accumulating | The biotech sector has underperformed the market for many years now, but there are reasons to be optimistic about this area of the market. Many biotech/biopharma stocks also make good covered call trade candidates due to the liquidity and lucrativeness of the option premiums against these equities. Stocks had their biggest decline last Friday since the first half of April due to escalating trade tensions between the U.S. and China. | Seeking Alpha | 2025-10-15 14:30:32 |
| Incyte's (INCY) EVP and General Counsel Sold 4,100 Shares for $352,000 | On October 2 and October 3, 2025, Sheila A. Denton, EVP & General Counsel of Incyte (INCY 0.47%), executed an option exercise and immediately sold 4,100 shares of common stock, as disclosed in this SEC Form 4 filing. | The Motley Fool | 2025-10-14 13:27:10 |
| Data from Incyte's TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025 | WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ESMO2025--Data from Incyte's TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the ESMO Congress 2025. | Business Wire | 2025-10-12 18:05:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 4 | 2026-01-08 | 2026-01-08 | View Filing |
| 4 | 2026-01-07 | 2026-01-07 | View Filing |
| 4 | 2026-01-05 | 2026-01-05 | View Filing |
| 4 | 2026-01-05 | 2026-01-05 | View Filing |
| 4 | 2026-01-05 | 2026-01-05 | View Filing |
| 4 | 2026-01-05 | 2026-01-05 | View Filing |
| 4 | 2026-01-05 | 2026-01-05 | View Filing |
| 4 | 2025-12-22 | 2025-12-22 | View Filing |
| 4 | 2025-12-18 | 2025-12-18 | View Filing |
| 4 | 2025-12-12 | 2025-12-12 | View Filing |
| 8-K | 2025-12-12 | 2025-12-12 | View Filing |
| 4 | 2025-12-10 | 2025-12-10 | View Filing |
| 4 | 2025-12-03 | 2025-12-03 | View Filing |
| 4 | 2025-12-03 | 2025-12-03 | View Filing |
| 4 | 2025-12-03 | 2025-12-03 | View Filing |
| 3 | 2025-12-03 | 2025-12-03 | View Filing |
| 4 | 2025-11-25 | 2025-11-25 | View Filing |
| 4 | 2025-11-19 | 2025-11-19 | View Filing |
| 4 | 2025-11-12 | 2025-11-12 | View Filing |
| SC 13G | 2025-11-10 | 2025-11-10 | View Filing |
| SC 13G | 2025-11-07 | 2025-11-07 | View Filing |
| 4 | 2025-11-07 | 2025-11-07 | View Filing |
| 4 | 2025-11-06 | 2025-11-06 | View Filing |
| 4 | 2025-11-05 | 2025-11-05 | View Filing |
| 144 | 2025-10-30 | 2025-10-30 | View Filing |
| 10-Q | 2025-10-28 | 2025-10-28 | View Filing |
| 8-K | 2025-10-28 | 2025-10-28 | View Filing |
| 144 | 2025-10-27 | 2025-10-27 | View Filing |
| SC 13G/A | 2025-10-17 | 2025-10-17 | View Filing |
| 4 | 2025-10-17 | 2025-10-17 | View Filing |
| 144 | 2025-10-16 | 2025-10-16 | View Filing |
| 144 | 2025-10-15 | 2025-10-15 | View Filing |
| 4 | 2025-10-06 | 2025-10-06 | View Filing |
| 4 | 2025-10-03 | 2025-10-03 | View Filing |
| 4 | 2025-10-03 | 2025-10-03 | View Filing |
| 8-K | 2025-10-03 | 2025-10-03 | View Filing |
| 144 | 2025-10-03 | 2025-10-03 | View Filing |
| 4 | 2025-10-02 | 2025-10-02 | View Filing |
| 4 | 2025-10-02 | 2025-10-02 | View Filing |
| 4 | 2025-10-02 | 2025-10-02 | View Filing |
| 144 | 2025-10-02 | 2025-10-02 | View Filing |
| 4 | 2025-09-24 | 2025-09-24 | View Filing |
| 3 | 2025-09-24 | 2025-09-24 | View Filing |
| 4 | 2025-09-18 | 2025-09-18 | View Filing |
| 144 | 2025-09-18 | 2025-09-18 | View Filing |
| 144 | 2025-09-16 | 2025-09-16 | View Filing |
| 4 | 2025-09-04 | 2025-09-04 | View Filing |
| 144 | 2025-09-02 | 2025-09-02 | View Filing |
| 4 | 2025-08-27 | 2025-08-27 | View Filing |
| 3 | 2025-08-27 | 2025-08-27 | View Filing |
| 4 | 2025-08-19 | 2025-08-19 | View Filing |
| 144 | 2025-08-15 | 2025-08-15 | View Filing |
| 144 | 2025-08-13 | 2025-08-13 | View Filing |
| 144 | 2025-08-12 | 2025-08-12 | View Filing |
| 8-K | 2025-08-07 | 2025-08-07 | View Filing |
| 4 | 2025-08-06 | 2025-08-06 | View Filing |
| 3 | 2025-08-05 | 2025-08-05 | View Filing |
| 144 | 2025-08-04 | 2025-08-04 | View Filing |
| 10-Q | 2025-07-29 | 2025-07-29 | View Filing |
| 8-K | 2025-07-29 | 2025-07-29 | View Filing |
| 4 | 2025-07-23 | 2025-07-23 | View Filing |
| 144 | 2025-07-21 | 2025-07-21 | View Filing |
| 4 | 2025-07-17 | 2025-07-17 | View Filing |
| 4 | 2025-07-17 | 2025-07-17 | View Filing |
| 4 | 2025-07-17 | 2025-07-17 | View Filing |
| 4 | 2025-07-17 | 2025-07-17 | View Filing |
| 4 | 2025-07-17 | 2025-07-17 | View Filing |
| 4 | 2025-07-17 | 2025-07-17 | View Filing |
| 4 | 2025-07-17 | 2025-07-17 | View Filing |
| 4 | 2025-07-16 | 2025-07-16 | View Filing |
| 4 | 2025-07-16 | 2025-07-16 | View Filing |
| 4 | 2025-07-16 | 2025-07-16 | View Filing |
| 4 | 2025-07-16 | 2025-07-16 | View Filing |
| 4 | 2025-07-16 | 2025-07-16 | View Filing |
| 4 | 2025-07-16 | 2025-07-16 | View Filing |
| 4 | 2025-07-16 | 2025-07-16 | View Filing |
| 4 | 2025-07-16 | 2025-07-16 | View Filing |
| 144 | 2025-07-16 | 2025-07-16 | View Filing |
| 144 | 2025-07-16 | 2025-07-16 | View Filing |
| 144 | 2025-07-16 | 2025-07-16 | View Filing |
| 144 | 2025-07-15 | 2025-07-15 | View Filing |
| 144 | 2025-07-15 | 2025-07-15 | View Filing |
| 144 | 2025-07-15 | 2025-07-15 | View Filing |
| 144 | 2025-07-14 | 2025-07-14 | View Filing |
| 4 | 2025-07-07 | 2025-07-07 | View Filing |
| 4 | 2025-07-07 | 2025-07-07 | View Filing |
| 4 | 2025-07-07 | 2025-07-07 | View Filing |
| 4 | 2025-07-07 | 2025-07-07 | View Filing |
| 4 | 2025-07-07 | 2025-07-07 | View Filing |
| 4 | 2025-07-07 | 2025-07-07 | View Filing |
| 4 | 2025-07-07 | 2025-07-07 | View Filing |
| 4 | 2025-07-07 | 2025-07-07 | View Filing |
| 144 | 2025-07-03 | 2025-07-03 | View Filing |
| 144 | 2025-07-03 | 2025-07-03 | View Filing |
| 4 | 2025-07-02 | 2025-07-02 | View Filing |
| 4 | 2025-07-02 | 2025-07-02 | View Filing |
| 4 | 2025-07-02 | 2025-07-02 | View Filing |
| 4 | 2025-07-02 | 2025-07-02 | View Filing |
| 4 | 2025-07-02 | 2025-07-02 | View Filing |
| S-8 | 2025-07-02 | 2025-07-02 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Williams PercentR Strategy | 52.49% | 0.99 | 436 | 0.05 | 0.17 | 42.99 |
| Larry Williams PercentR Strategy | 41.94% | 1.02 | 217 | 0.04 | 0.12 | 32.45 |
| Bollinger Bands Strategy | 25.28% | 1.04 | 111 | 0.04 | 0.16 | 15.79 |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | x | xxxx | xxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | x | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | x | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | x | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | x | xxxxx |
| xxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | xxxxx | xxxxx | xx |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |